https://www.avient.com/sites/default/files/resources/PDI_Healthcare_Brochure_2011_0.pdf
Equipment Benefi t
Scanning Electron Microscopy with
Energy Dispersive X-ray System
Capability to look at material and property defects at the most detailed level
with magnifi cation up to 800,000x
Digital Optical Microscope Ability to non-destructively capture fully-focused images with a
depth-of-fi eld 20x larger than conventional microscopes
Microwave Sample Digestion System Aids in sample preparation for heavy metal analysis
Mechanical Spectrometer Estimates how a medical device will structurally perform when subjected to
the load within a human body
Differential Scanning Calorimeter Analyzes the transition temperatures of materials and also determines the
purity of the materials to predict likelihood of defects
Chromatography Accessories Facilitates compositional analysis of materials and devices as well as the
ability to analyze extractables
Copyright © 2011, Polymer Diagnostics Inc.
Was it due to composition?
Was it due to composition?
https://www.avient.com/sites/default/files/2021-03/packaging-solutions-for-film-sheet-product-selection-guide.pdf
PACKAGING
SOLUTIONS
Film & Sheet
SELECTION GUIDE
Anti-block BOPET application (PV back sheet, packaging film, industry film)
Sleeve application (PETG)
Anti-static Migrating anti-static system
Flame retardant Halogen free flame retardant system, transparent, UL94 VTM-0
Light stabilizer Protection for outdoor application (UV 380nm)
Protection for screen application (UV 400nm)
Matting agent Matting agent
Pinning agent Increased conductivity
O2 scavenger Content protection against oxygen
White masterbatch Blue shade white
Standard white
Black masterbatch Carbon black
Cool black system
BOPET STANDARD PRODUCT PORTFOLIO
Anti-block
Standard anti-block
Printable A/B/A PET sheet and film
High-transparent and low COF
Anti-static A/B/A film or sheet (transparency)
A/B/A film or sheet (matte)
Impact modifier Improve sheet elongation at low temperature
Chain extender IV improver, EU food and FDA approved
White masterbatch Standard white
Matting agent Surface matting agent
APET SHEET PRODUCT PORTFOLIO
Slip agent Mainly used for multilayer PE/PP film and composite film
Anti-block Pure anti-block can be used in transparent film
Contain both anti-block and slip agent for polyolefin film
Processing masterbatch Used in blowing and tape casting of PE/PP (liquid)
Anti-oxidant Protection of film from degrading while processing
Increase reclaimed ingredients in the formula
Light stabilizer
Protection of content
Low precipitation, which is especially suitable for thinner
PE products, such as film and spinning
Anti-fog Good resistance to cold and hot fog,
and suitable for thinner film
Anti-static Applicable to multilayer PE/PP film and composite film
PO SHEET PRODUCT PORTFOLIO
www.avient.com
Copyright © 2021, Avient Corporation.
https://www.avient.com/sites/default/files/2022-09/Avient Discontinued Operations Financial Information.pdf
Certain corporate costs previously allocated to Avient Distribution will be retained by Avient and have been recast as costs in
continuing operations.
G A A P I N C O M E S TAT E M E N T R E C A S T F O R A V I E N T D I S T R I B U T I O N A S A
D I S C O N T I N U E D O P E R AT I O N
Avient Corporation 3
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 YTD 2022
Sales 826.0$ 864.5$ 818.0$ 807.1$ 3,315.6$ 892.2$ 891.0$ 1,783.2$
Cost of sales 562.9 615.9 602.4 590.5 2,371.7 637.8 630.1 1,267.9
Gross margin 263.1 248.6 215.6 216.6 943.9 254.4 260.9 515.3
Selling and administrative 168.7 166.2 162.8 166.4 664.1 152.2 160.8 313.0
Operating income 94.4 82.4 52.8 50.2 279.8 102.2 100.1 202.3
Interest expense, net (19.3) (19.5) (19.0) (17.5) (75.3) (16.9) (16.2) (33.1)
Other income (expense), net 1.6 1.1 1.6 (5.3) (1.0) (0.6) 1.6 1.0
Income before income taxes 76.7 64.0 35.4 27.4 203.5 84.7 85.5 170.2
Income tax (expense) benefit (16.3) (13.8) (2.0) (16.2) (48.3) (20.0) (22.7) (42.7)
Net income from continuing operations 60.4 50.2 33.4 11.2 155.2 64.7 62.8 127.5
Net income from discontinued operations, net of income taxes 19.3 19.2 19.2 17.7 75.4 19.8 21.9 41.7
Net income 79.7 69.4 52.6 28.9 230.6 84.5 84.7 169.2
Net (income) loss attributable to noncontrolling interests (0.4) (0.6) 0.3 0.9 0.2 (0.3) - (0.3)
Net income attributable to Avient common shareholders 79.3$ 68.8$ 52.9$ 29.8$ 230.8$ 84.2$ 84.7$ 168.9$
Earnings per share attributable to Avient common shareholders - Basic
Continuing operations 0.66$ 0.54$ 0.37$ 0.13$ 1.70$ 0.70$ 0.69$ 1.39$
Discontinued operations 0.21$ 0.21$ 0.21$ 0.20$ 0.83$ 0.22$ 0.24$ 0.46$
Total 0.87$ 0.75$ 0.58$ 0.33$ 2.53$ 0.92$ 0.93$ 1.85$
Earnings per share attributable to Avient common shareholders - Diluted
Continuing operations 0.65$ 0.54$ 0.37$ 0.13$ 1.69$ 0.70$ 0.68$ 1.38$
Discontinued operations 0.21$ 0.20$ 0.20$ 0.19$ 0.82$ 0.21$ 0.24$ 0.45$
Total 0.86$ 0.74$ 0.57$ 0.32$ 2.51$ 0.91$ 0.92$ 1.83$
A D J U S T E D F I N A N C I A L I N F O R M AT I O N R E C A S T F O R A V I E N T D I S T R I B U T I O N A S A
D I S C O N T I N U E D O P E R AT I O N
Avient Corporation 4
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 YTD 2022
Sales 826.0$ 864.5$ 818.0$ 807.1$ 3,315.6$ 892.2$ 891.0$ 1,783.2$
Cost of sales 565.1 603.3 585.1 584.6 2,338.1 632.0 632.1 1,264.1
Gross margin 260.9 261.2 232.9 222.5 977.5 260.2 258.9 519.1
Selling and administrative 164.1 164.6 160.1 161.1 649.9 151.3 157.0 308.3
Operating income 96.8 96.6 72.8 61.4 327.6 108.9 101.9 210.8
Interest expense, net (19.3) (19.5) (19.0) (17.5) (75.3) (16.9) (16.2) (33.1)
Other income (expense), net 1.6 1.1 1.5 4.1 8.3 (0.7) 0.7 0.0
Income before income taxes 79.1 78.2 55.3 48.0 260.6 91.3 86.4 177.7
Income tax expense (16.1) (16.3) (10.2) (12.8) (55.4) (20.2) (20.4) (40.6)
Net income from continuing operations 63.0 61.9 45.1 35.2 205.2 71.1 66.0 137.1
Net (income) loss attributable to noncontrolling interests
(0.4) (0.6) 0.3 0.9 0.2 (0.3) - (0.3)
Adjusted Net income attributable to Avient common
shareholders - continuing operations 62.6$ 61.3$ 45.4$ 36.1$ 205.4$ 70.8$ 66.0$ 136.8$
Adjusted earnings per share attributable to Avient
common shareholders - Diluted 0.68$ 0.66$ 0.49$ 0.39$ 2.23$ 0.77$ 0.72$ 1.48$
Weighted average diluted Shares 92.2 92.4 92.2 92.4 92.1 92.3 92.1 92.2
S E G M E N T D ATA R E C A S T F O R AV I E N T D I S T R I B U T I O N A S A D I S C O N T I N U E D
O P E R AT I O N
Avient Corporation 5
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 2022 YTD
Sales:
Color, Additives and Inks 609.3$ 624.4$ 586.6$ 581.3$ 2,401.6$ 649.5$ 649.1$ 1,298.6$
Specialty Engineered Materials 214.7 238.9 231.7 226.3 911.6 243.1 242.3 485.4
Corporate and Eliminations 2.0 1.2 (0.3) (0.5) 2.4 (0.4) (0.4) (0.8)
Sales 826.0 864.5 818.0 807.1 3,315.6 892.2 891.0 1,783.2
Gross Margin:
Color, Additives and Inks 197.5$ 193.4$ 172.1$ 164.5$ 727.5$ 192.1$ 193.4$ 385.5$
Specialty Engineered Materials 63.1 68.1 61.4 58.3 250.9 68.4 66.0 134.4
Corporate and Eliminations 2.5 (12.9) (17.9) (6.2) (34.5) (6.1) 1.5 (4.6)
Gross Margin 263.1 248.6 215.6 216.6 943.9 254.4 260.9 515.3
Selling and Administrative Expense:
Color, Additives and Inks 108.7$ 107.1$ 105.3$ 103.3$ 424.4$ 97.6$ 99.8$ 197.4$
Specialty Engineered Materials 30.5 32.3 31.4 31.2 125.4 30.1 30.8 60.9
Corporate and Eliminations 29.5 26.8 26.1 31.9 114.3 24.5 30.2 54.7
Selling and Administrative Expense 168.7 166.2 162.8 166.4 664.1 152.2 160.8 313.0
Operating Income:
Color, Additives and Inks 88.8$ 86.3$ 66.8$ 61.2$ 303.1$ 94.5$ 93.6$ 188.1$
Specialty Engineered Materials 32.6 35.8 30.0 27.1 125.5 38.3 35.2 73.5
Corporate and Eliminations (27.0) (39.7) (44.0) (38.1) (148.8) (30.6) (28.7) (59.3)
Operating Income 94.4 82.4 52.8 50.2 279.8 102.2 100.1 202.3
Earnings Before Interest, Taxes,
Depreciation and Amortization (EBITDA):
Color, Additives and Inks 116.2$ 111.6$ 93.4$ 87.6$ 408.8$ 120.5$ 119.5$ 240.0$
Specialty Engineered Materials 40.4 43.9 37.9 35.1 157.3 46.1 42.9 89.0
Corporate and Eliminations (25.3) (39.5) (41.9) (34.6) (141.3) (26.8) (26.0) (52.8)
Other income (expense) 1.6 1.1 1.6 (5.3) (1.0) (0.6) 1.6 1.0
EBITDA 132.9 117.1 91.0 82.8 423.8 139.2 138.0 277.2
N O N - G A A P R E C O N C I L I AT I O N S F O R R E C A S T H I S T O R I C A L R E S U LT S
Avient Corporation 6
Special
Adjusted
Special
Adjusted
Special
Adjusted
Special
Adjusted
Special
Adjusted
Sales $ 826.0 $ - $ 826.0 $ 864.5 $ - $ 864.5 $ 818.0 $ - $ 818.0 $ 807.1 $ - $ 807.1 $ 3,315.6 $ - $ 3,315.6
Gross margin 263.1 (2.2) 260.9 248.6 12.6 261.2 215.6 17.3 232.9 216.6 5.9 222.5 943.9 33.6 977.5
Selling and administrative expense 168.7 (4.6) 164.1 166.2 (1.6) 164.6 162.8 (2.7) 160.1 166.4 (5.3) 161.1 664.1 (14.2) 649.9
Operating income 94.4 2.4 96.8 82.4 14.2 96.6 52.8 20.0 72.8 50.2 11.2 61.4 279.8 47.8 327.6
Interest expense, net (19.3) - (19.3) (19.5) - (19.5) (19.0) - (19.0) (17.5) - (17.5) (75.3) - (75.3)
Other income (expense), net 1.6 - 1.6 1.1 - 1.1 1.6 (0.1) 1.5 (5.3) 9.4 4.1 (1.0) 9.3 8.3
Income taxes (16.3) 0.2 (16.1) (13.8) (2.5) (16.3) (2.0) (8.2) (10.2) (16.2) 3.4 (12.8) (48.3) (7.1) (55.4)
Net income (loss) attributable to noncontrolling
interests
(0.4) - (0.4) (0.6) - (0.6) 0.3 - 0.3 0.9 - 0.9 0.2 - 0.2
Net income from continuing operations attributable
to Avient shareholders
$ 60.0 $ 2.6 $ 62.6 $ 49.6 $ 11.7 $ 61.3 $ 33.7 $ 11.7 $ 45.4 $ 12.1 $ 24.0 $ 36.1 $ 155.4 $ 50.0 $ 205.4
Net income / EPS $ 0.65 0.03 $ 0.68 $ 0.54 0.13 $ 0.66 $ 0.37 0.13 $ 0.49 $ 0.13 $ 0.26 $ 0.39 $ 1.69 0.54 $ 2.23
Weighted-average diluted shares 92.2 92.2 92.2 92.4 92.4 92.4 92.2 92.2 92.2 92.4 92.4 92.4 92.1 92.1 92.1
Three Months Ended
December 31, 2021
Year Ended
December 31, 2021
Three Months Ended
March 31, 2021
Three Months Ended
June 30, 2021
Three Months Ended
September 30, 2021
N O N - G A A P R E C O N C I L I AT I O N S F O R R E C A S T H I S T O R I C A L R E S U LT S
Avient Corporation 7
Special
Adjusted
Special
Adjusted
Special
Adjusted
Sales $ 892.2 $ - $ 892.2 $ 891.0 $ - $ 891.0 $ 1,783.2 $ - $ 1,783.2
Gross margin 254.4 5.8 260.2 260.9 (2.0) 258.9 515.3 3.8 519.1
Selling and administrative expense 152.2 (0.9) 151.3 160.8 (3.8) 157.0 313.0 (4.7) 308.3
Operating income 102.2 6.7 108.9 100.1 1.8 101.9 202.3 8.5 210.8
Interest expense, net (16.9) - (16.9) (16.2) - (16.2) (33.1) - (33.1)
Other (expense) income, net (0.6) (0.1) (0.7) 1.6 (0.9) 0.7 1.0 (1.0) 0.0
Income taxes (20.0) (0.2) (20.2) (22.7) 2.3 (20.4) (42.7) 2.1 (40.6)
Net income attributable to noncontrolling interests (0.3) - (0.3) - - - (0.3) - (0.3)
Net income from continuing operations attributable
to Avient shareholders
$ 64.4 $ 6.4 $ 70.8 $ 62.8 $ 3.2 $ 66.0 $ 127.2 $ 9.6 $ 136.8
Net income / EPS $ 0.70 0.07 $ 0.77 $ 0.68 0.03 $ 0.72 $ 1.38 0.10 1.48
Weighted-average diluted shares 92.3 92.3 92.3 92.1 92.1 92.1 92.2 92.2 92.2
Three Months Ended
March 31, 2022
Three Months Ended
June 30, 2022
Six Months Ended
June 30, 2022
N O N - G A A P R E C O N C I L I AT I O N S F O R R E C A S T A D J U S T E D E B I T D A
Avient Corporation 8
EBITDA Reconciliation Q1 2021 Q2 2021 Q3 2021 Q4 2021 YTD 2021 Q1 2022 Q2 2022 YTD 2022
Net income from continuing operations – GAAP 60.4$ 50.2$ 33.4$ 11.2$ 155.2$ 64.7$ 62.8$ 127.5$
Income tax expense 16.3 13.8 2.0 16.2 48.3 20.0 22.7 42.7
Interest expense, net 19.3 19.5 19.0 17.5 75.3 16.9 16.2 33.1
Depreciation and amortization from continuing operations 36.9 33.6 36.6 37.9 145.0 37.6 36.3 73.9
EBITDA 132.9 117.1 91.0 82.8 423.8 139.2 138.0 277.2
Special items, before tax 2.4 14.2 19.9 20.6 57.1 6.6 0.9 7.5
Depreciation and amortization included in special items (0.6) 1.4 (0.9) (1.6) (1.7) (2.1) (1.1) (3.2)
Adjusted EBITDA 134.7$ 132.7$ 110.0$ 101.8$ 479.2$ 143.7$ 137.8$ 281.5$
S U M M A R Y O F S P E C I A L I T E M S
Avient Corporation 9
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 2022 YTD
Cost of sales:
Restructuring costs, including accelerated depreciation (1.8)$ (1.5)$ (5.3)$ (6.0)$ (14.6)$ (4.4)$ (2.6)$ (7.0)$
Environmental remediation costs (0.5) (12.5) (9.4) (0.5) (22.9) (2.0) (3.0) (5.0)
Reimbursement of previously incurred environmental costs 4.5 - - - 4.5 0.6 7.6 8.2
Acquisition related adjustments - 1.4 (2.6) 0.6 (0.6) - - -
Impact on cost of sales 2.2 (12.6) (17.3) (5.9) (33.6) (5.8) 2.0 (3.8)
Selling and administrative expense:
Restructuring, legal and other (1.3) (1.4) - (4.2) (6.9) 2.0 (1.7) 0.3
Acquisition/divestiture related costs (3.3) (0.2) (2.7) (1.1) (7.3) (2.9) (2.1) (5.0)
Impact on selling and administrative expense (4.6) (1.6) (2.7) (5.3) (14.2) (0.9) (3.8) (4.7)
Impact on operating income (2.4) (14.2) (20.0) (11.2) (47.8) (6.7) (1.8) (8.5)
Other income, net - - 0.1 (9.4) (9.3) 0.1 0.9 1.0
Impact on income before income taxes (2.4) (14.2) (19.9) (20.6) (57.1) (6.6) (0.9) (7.5)
Income tax benefit on above special items 0.9 3.4 4.6 4.1 13.0 1.7 0.2 1.9
Tax adjustments (1.1) (0.9) 3.6 (7.5) (5.9) (1.5) (2.5) (4.0)
Impact of special items on net income (2.6)$ (11.7)$ (11.7)$ (24.0)$ (50.0)$ (6.4)$ (3.2)$ (9.6)$
https://www.avient.com/sites/default/files/2021-04/trilliant-hc8900-medical-device-housing-case-study.pdf
DEVICE
MANUFACTURER
M E D I C A L D E V I C E H O U S I N G
• Improved chemical resistance compared to PC/ABS,
PC/PET & COPE
• Flame retardant (FR) rating of V-1 at 0.75 mm
• Zero BPA & non-halogenated FR material
• Available in standard hospital grade pre-colors
• Provided a cost-effective material with superior
chemical resistance to traditional materials
• Formulated a medical-grade, semi-crystalline
blend to support regulatory testing and
approvals
• Demonstrated superior property retention and
crack resistance after exposure to hospital-
grade disinfectants, including Virex® Tb,
helping to extend the device life
Trilliant™ HC8900 Thermoplastics
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics